|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell.
|
8204007 |
1994 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Neuroendocrine cells, p53, c-myc, c-erbB-2 and bcl-2 were rarely co-expressed at any stage of prostate cancer.
|
8532388 |
1995 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The expression of bcl-2 or accumulation of p53 protein in prostate cancer metastases did not significantly influence patient survival or the extent of metastatic disease.
|
8996359 |
1997 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Protein expression of BCL-2 in prostate cancer is highly correlated with cancer progression and androgen-independent phenotype.
|
9090501 |
1997 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
To determine whether oligo-induced growth factor deprivation therapy similarly enhanced expression of bcl-2 (as follows androgen deprivation) human prostate cancer derived PC-3 cells were treated in vitro with oligos directed against TGF-alpha (MR-1) and/or EGFR (MR-2).
|
9232607 |
1997 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The contribution of bcl2 to the regulation of the arachidonate pathway for prostate carcinoma cell survival was also investigated using highly selective inhibitors of arachidonate metabolism.
|
9260915 |
1997 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma.
|
9366376 |
1997 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
By efficiently destroying the intracellular bcl-2 mRNA, one might be able to make the prostate cancer cell responsive again to conventional apoptotic stimuli such as androgen withdrawal.
|
9413164 |
1998 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Bcl-2 protein is one of the key inhibitors of apoptosis and is often unregulated in advanced prostate cancer.
|
9514052 |
1998 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
However, for prostate cancer in black men there was a significant association between bcl-2 immunopositivity and higher S-phase fractions.
|
9598502 |
1998 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The analysis of p53, bcl-2, Ki-67, and angiogenesis revealed that only increasing p53 expression and positive family history of PCa approached significance (P = 0.057).
|
9609635 |
1998 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Because inherent cellular radioresistance plays a critical role in the failure of radiotherapy, in this study, we investigated whether there is a correlation between the ratio of two apoptosis regulators, bcl-2 (apoptosis suppressor) and bax (apoptosis inducer) in prostatic tumors and the clinical response to radiotherapy in patients with localized prostate cancer.
|
9836559 |
1998 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Conversely, Bcl-2+ immunostaining was observed in only 7/36 CaP (in 4/18 hormone-treated and 3/18 untreated patients).
|
9842970 |
1998 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These results emphasize the significance of bcl-2 expression during prostate cancer progression and suggest possible mechanisms for the acquisition of androgen-independent tumor growth.
|
9852630 |
1998 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of bcl-2 occurs frequently in prostate cancer and is associated with both hormonal therapy and chemotherapy resistance.
|
10190792 |
1999 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our group recently has also shown that bcl-2 protein expression in primary CaP is a predictor of cancer recurrence after radical prostatectomy.
|
10325496 |
1999 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
One androgen-insensitive prostate cancer cell line, DU-145, lacking in bcl-2 expression, was found to be completely refractory to the effects of the virus ribozyme, supporting the concept that the cytotoxic effects of the ribozyme are based solely on its effects on bcl-2 expression.
|
10446452 |
1999 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
To investigate the effect of bcl-2-mediated anti-apoptotic ability on tumor growth and progression in prostate cancer, a cell line overexpressing bcl-2 (LNCaP/bcl-2) was established by genetically engineering a prostate cancer cell line LNCaP.
|
10533903 |
1999 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer.
|
10884916 |
2000 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.
|
10945499 |
2000 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Both Bcl-xL and Bcl-2, antiapoptotic members of the Bcl family, are found in prostate cancer cell lines.
|
11085527 |
2000 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In vivo, xenograft tumors derived from the bcl-2-overexpressing prostate carcinoma cell lines displayed increased angiogenic potential and grew more aggressively than tumors derived from the control cell lines (P =.03 for PC3).
|
11158189 |
2001 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
These findings identify combined antisense Bcl-2 and paclitaxel as a potentially new therapeutic strategy for advanced prostate cancer by enhancing paclitaxel chemosensitivity and delaying progression of hormone-refractory prostate cancer.
|
11275990 |
2001 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Bcl-2 correlates with tumor ploidy and nuclear morphology in early stage prostate carcinoma. A fine needle aspiration biopsy study.
|
11482579 |
2001 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Restoring the balance of Bcl-2 family members may result in the induction of apoptosis in prostate cancer cells previously resistant to treatment.
|
11571575 |
2001 |